
First Patient Randomized in Phase 2 Trial for NSCLC Treatment Combination
The first patient was randomized in the phase 2 trial examining Tedopi and Opdivo for non-small cell lung cancer.
OSE Immunotherapeutics SA and the FoRT Foundation announced last week that the first patient was randomized to receive treatment in the phase 2 trial of Tedopi and Opdivo (nivolumab).
The combination therapy will be given as a second-line treatment to patients with HLA-A2-positive metastatic non-small cell lung cancer (NSCLC). Patients will be randomized to receive either Tedopi and Opdivo – which is a PD-1 targeted checkpoint immune inhibitor – , Tedopi plus chemotherapy or chemotherapy alone.
Tedopi is a neo-epitope-based vaccine that activates T lymphocytes, which researchers hope will optimize the checkpoint inhibitor or chemotherapy in patients who have become resistant.
“We look forward to evaluating this second-line combination of immuno-therapeutic agents in NSCLC patients with disease progression, a population who needs new treatment options,” said Dr. Federico Cappuzzo, director of medical oncology at Cancer Institute Regina Elena,
The trial will have 105 patients, and results are expected in 2024.
For more news on cancer updates, research and education, don’t forget to